Bright Minds Biosciences

DRUG · CANADIAN

$52.48−$0.21 (−0.40%)TodayMarket closed · Oct 23, 7:50 PM ET

Prev close $52.69

About DRUG

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York. The company went IPO on 2021-02-08. The firm is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Employees: 0
Headquarters: New York City, New York
Listed: Feb 8, 2021
Sector: Health Care
Industry: Biotechnology
Website: brightmindsbio.com

Leadership

Bright Minds Biosciences executives
Name	Title	Since	Age
Ian Mcdonald	—	2019	37
Ryan Cheung	—	—	46
Jan Pedersen	—	2022	60
Stephen Collins	—	—	—
Nils Bottler	—	—	37
Jeremy Fryzuk	—	—	39
David Weiner	—	—	60

Similar companies

Companies in the same industry as Bright Minds Biosciences

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.